Literature DB >> 7908221

High-dose therapy: the Third UCH Meeting.

R Chopra1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7908221      PMCID： PMC1968826          DOI： 10.1038/bjc.1994.149

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  11 in total

1.  Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia.

Authors:  C E Dunbar; F M Stewart
Journal:  Blood       Date:  1992-03-01       Impact factor: 22.113

2.  Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study.

Authors:  B Löwenberg; L J Verdonck; A W Dekker; R Willemze; F E Zwaan; M de Planque; J Abels; P Sonneveld; J van der Lelie; R Goudsmit
Journal:  J Clin Oncol       Date:  1990-02       Impact factor: 44.544

3.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

4.  A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission.

Authors:  A R Zander; M Keating; K Dicke; D Dixon; S Pierce; S Jagannath; L Peters; L Horwitz; K Cockerill; G Spitzer
Journal:  J Clin Oncol       Date:  1988-10       Impact factor: 44.544

5.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

Authors:  F Mandelli; G Avvisati; S Amadori; M Boccadoro; A Gernone; V M Lauta; F Marmont; M T Petrucci; M Tribalto; M L Vegna
Journal:  N Engl J Med       Date:  1990-05-17       Impact factor: 91.245

6.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma.

Authors:  R J Berenson; W I Bensinger; R S Hill; R G Andrews; J Garcia-Lopez; D F Kalamasz; B J Still; G Spitzer; C D Buckner; I D Bernstein
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

7.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.

Authors:  A Osterborg; M Björkholm; M Björeman; G Brenning; K Carlson; F Celsing; G Gahrton; G Grimfors; H Gyllenhammar; R Hast
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

8.  Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up.

Authors:  F R Appelbaum; L D Fisher; E D Thomas
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

9.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.

Authors:  N A Kernan; G Bartsch; R C Ash; P G Beatty; R Champlin; A Filipovich; J Gajewski; J A Hansen; J Henslee-Downey; J McCullough
Journal:  N Engl J Med       Date:  1993-03-04       Impact factor: 91.245

10.  Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy.

Authors:  R E Champlin; W G Ho; R P Gale; D Winston; M Selch; R Mitsuyasu; C Lenarsky; R Elashoff; J Zighelboim; S A Feig
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.